The MTD/RP2D was investigated in the expansion phase of this study (to be published separately) in patients with previously treated SCLC (both limited-stage [LS] and extensive-stage [ES]), whose tumours are expected to be sensitive to AURKB inhibition due to the characteristic rapid proliferation and reliance on accelerated mitosis of SCLC. This evidence concerns the gene AURKB and neoplasm.